Ascelia Pharma AB (FRA:7ZA) GF Score: 28/100 (As of Jul. 17, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7ZA Ascelia Pharma AB FRA:7ZA
28 GF Score
Price €0.00
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB GF Score?

Ascelia Pharma AB FRA:7ZA -99.85% 28 GF Score is 28 as of Jul. 17, 2026, which is 7% below its 10-year median of 30.00. GuruFocus rates FRA:7ZA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Ascelia Pharma AB has the GF Score of 28, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 7/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 5/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Ascelia Pharma AB might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Ascelia Pharma AB  (FRA:7ZA) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Ascelia Pharma AB GF Score Related Terms

FRA:7ZA vs VRTX, REGN, ALNY: GF Score Comparison

For the Biotechnology subindustry, Ascelia Pharma AB's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascelia Pharma AB GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's GF Score distribution charts can be found below:

* The bar in red indicates where Ascelia Pharma AB's GF Score falls into.


FRA:7ZA
28GF Score
Ascelia Pharma AB FRA:7ZA
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 28 mean?
Ascelia Pharma AB (FRA:7ZA) has a GF Score of 28 as of Jul. 17, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Ascelia Pharma AB and its competitors. This is near median its historical median of 30.00. Over the past decade, Ascelia Pharma AB's GF Score has ranged from 10.00 to 41.00.
Is Ascelia Pharma AB's GF Score too high?
Ascelia Pharma AB's current GF Score of 28 is near median its 10-year median of 30.00. Over the past 10 years, this metric has ranged from a low of 10.00 to a high of 41.00. Overall, Ascelia Pharma AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's GF Score compare to VRTX and REGN?
Ascelia Pharma AB's GF Score of 28 can be compared against companies in the Biotechnology industry. Historically, Ascelia Pharma AB's own GF Score has ranged from 10.00 to 41.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Ascelia Pharma AB and its competitors. Ascelia Pharma AB's current GF Score is 28, which is near median its own 10-year median of 30.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (FRA:7ZA) has a current GF Score of 28. The current GF Score is 28, which is near median its 10-year median of 30.00. Ascelia Pharma AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Ascelia Pharma AB (FRA:7ZA), the current GF Score is 28 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Other Exchanges ACE:SwedenACEs:UK
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
28GF Score

Get the complete analysis for FRA:7ZA

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.00
Price